Research antioxidant activity of chitooligosacchride by UV-VIS absorption spectrocopy

Chitosan with 80% degree of deacetylation was hydrolyzed by cellulase of Trichoderma viride to prepare chitooligosaccharides (COSs) by the fractionation of the COSs with ultrafiltration membrane. The antioxidant activities of the COSs were clarified in this study by reducing power and free radical scavenging ability assay by UV-VIS absorption spectrum. The results show that the COS 1 (10,000-5,000 Da), COS 2 (5,000-3,000 Da), COS 3 (3,000-1,000 Da) and COS 4 (less than1,000 Da) segments have antioxidant properties.The antioxidant activitives of the COSs increased with the increment of concentration, and they also depended on molecular weight

Antiproliferative Effect of Aminoethyl-Chitooligosaccharide on Human Lung A549 Cancer Cells

The aminoethyl−chitooligosaccharide (AE-COS) was reported to inhibit human gastric cancer cell proliferation and human fibrosarcoma cell invasion. In this study, the role of AE-COS in down-regulation of proliferation of human lung A549 cancer cells was evaluated. It was found that AE-COS was able to reduce A549 cell proliferation to (32 ± 1.3)% at a concentration of 500 µg/mL. Moreover, AE-COS treatment caused suppression on COX-2 expression in a dose-dependent manner. Notably, the role of AE-COS in induction of cell apoptosis was observed via decreasing Bcl-2 expression and increasing caspase-3 and -9 activation. Accordingly, the antiproliferative effect of AE-COS was indicated due to suppression of cell proliferation and induction of cell apoptosis, suggesting AE-COS as a promising chemotherapy agent for treatment of lung cancer

Investigation of Biological Activities of Wild Bitter Melon (<i>Momordica charantia</i> Linn. Var. Abbreviata Ser.)

Wild bitter melon (Momordica charantia L. var. Abbreviata Ser.) is a wild edible variety of M. charantia, often used in folk medicine. In this study, the biological activities of its extract and fractions were investigated in vitro. It was found that ethyl acetate (EA) fraction exhibited high 1,1-diphenyl-2-picryl-hydrazyl (DPPH) scavenging activity with a half maximal inhibitory concentration (IC50) value of 0.43 &#177; 0.04 mg/mL, while the chloroform (CF), EA, and n-butanol (Bu) fractions had strong 2,2-azinobis-3-ethyl benzothiazoline-6-sulfonic acid (ABTS)+ scavenging ability with IC50 values of 0.36 &#177; 0.04 mg/mL, 0.35 &#177; 0.02 mg/mL, and 0.35 &#177; 0.05 mg/mL, respectively. Moreover, the EA and Bu fractions exhibited the highest protective effect against H2O2-induced DNA damage in a concentration-dependent manner. Furthermore, the EA fraction was effective in the inhibition of enzyme &#945;-amylase activity with an IC50 value of 0.27 &#177; 0.029 mg/mL. Finally, it was observed that the production of nitric oxide (NO), a pro-inflammatory mediator, was significantly reduced from LPS-stimulated murine macrophage RAW 264.7 cells by the ethanol extract (ET) and the EA fraction. Therefore, wild bitter melon could be considered as a promising biomaterial for the development of pharmaceutical products

Mechanism of Action of Mangifera indica Leaves for Anti-Diabetic Activity

Diabetes is a major metabolic disorder whose prevalence is increasing daily. Medicinal plants have played an important role in the prevention and treatment of type 2 diabetes via prophylactic and therapeutic management. In this study, Mangifera Indica leaf (MIL) extract was investigated for its promising anti-diabetic activity via an in vitro model. It was found that MIL extract possessed significant inhibition on alpha-amylase activity up to (51.4 &plusmn; 2.7)% at a concentration of 200 &micro;g/mL. Moreover, glucose adsorption capacity of MIL was identified at (2.7 &plusmn; 0.19) mM glucose/g extract. Furthermore, the extract caused a significant increase in glucose uptake up to (143 &plusmn; 9.3)% in LO-2 liver cells. Notably, MIL extract was effective in scavenging (63.3 &plusmn; 2.1)% 1,1-diphenyl-2-picryl-hydrazyl (DPPH) and (71.6 &plusmn; 4.3)% 2,2-azinobis-3-ethyl benzothiazoline-6-sulfonic acid (ABTS)+ radicals and inhibiting (66 &plusmn; 4.9)% NO production from RAW264.7 cells without any cytotoxicity effects. Accordingly, M. indica leaves are suggested as a promising material for development of hypoglycemic products

The Suppressive Activity of Fucofuroeckol-A Derived from Brown Algal Ecklonia stolonifera Okamura on UVB-Induced Mast Cell Degranulation

UV light, especially UVB, is known as a trigger of allergic reaction, leading to mast cell degranulation and histamine release. In this study, phlorotannin Fucofuroeckol-A (F-A) derived from brown algal Ecklonia stolonifera Okamura was evaluated for its protective capability against UVB-induced allergic reaction in RBL-2H3 mast cells. It was revealed that F-A significantly suppress mast cell degranulation via decreasing histamine release as well as intracellular Ca2+ elevation at the concentration of 50 μM. Moreover, the inhibitory effect of F-A on IL-1β and TNF-α productions was also evidenced. Notably, the protective activity of F-A against mast cell degranulation was found due to scavenging ROS production. Accordingly, F-A from brown algal E. stolonifera was suggested to be promising candidate for its protective capability against UVB-induced allergic reaction

Ferulic acid grafted onto chitooligosaccharides attenuates LPS-stimulated in murine macrophages by modulating the NF-κB and MAPK pathways

Although chitooligosaccharides (COS) improve the drawbacks of chitosan, their biological activities in medical applications have not been highly appreciated. The main approach is to synthesise the COS derivatives in order to improve the biological properties of the COS. In this study, ferulic acid (FA) grafted onto COS (FA-COS) were synthesised and their mechanism of anti-inflammatory activity was investigated in the murine macrophage cells. The synthesis conditions of FA-COS were optimised and confirmed that the FA was successfully conjugated onto COS with the grafting effect of 15-34%. FA-COS exhibited anti-inflammatory activities via suppressing of nitric oxide formation, reducing iNOS expression at transcription and translation levels, down-regulation of TNF-α, IL-6 and IL-1 β genes; NF-κB and MAPKs signalling pathways. These results show anti-inflammatory molecular mechanism of FA-COS that exhibit enormous potential for prevention of inflammatory diseases.</p

Highly Active Astaxanthin Production from Waste Molasses by Mutated <i>Rhodosporidium toruloides</i> G17

Astaxanthin is increasingly attracting commercial interest for its application in the nutraceutical and pharmaceutical industries. This study aimed to produce astaxanthin from molasses with our newly mutated strain of Rhodosporidium toruloides G17 and to evaluate biological activities of the produced astaxanthin. To maximize the astaxanthin yield, the response surface methodology was used so as to optimize the culture conditions. A maximum astaxanthin yield of 1262.08 ± 14.58 µg/L was achieved by growing R. toruloides G17 in a molasses-based medium containing 49.39 g/L reducing sugar, 1.00 g/L urea, 4.15 g/L MgSO4·7H2O, and 10.05% inoculum ratio. The produced astaxanthin was then purified and studied for its antioxidant and anticancer activities. This compound exhibited 123-fold higher antioxidant activity than α-tocopherol, with an IC50 value of 0.97 ± 0.01 µg/mL. The astaxanthin also showed a potent inhibitory ability against the following three cancer cell lines: HeLa, A549, and MCF7, with IC50 values of 69.07 ± 2.4 µg/mL, 55.60 ± 2.64 µg/mL, and 56.38 ± 4.1 µg/mL, respectively. This study indicates that astaxanthin derived from our newly mutated R. toruloides G17 is a promising anticancer and antioxidant agent for further pharmaceutical applications

Highly Active Astaxanthin Production from Waste Molasses by Mutated Rhodosporidium toruloides G17

Astaxanthin is increasingly attracting commercial interest for its application in the nutraceutical and pharmaceutical industries. This study aimed to produce astaxanthin from molasses with our newly mutated strain of Rhodosporidium toruloides G17 and to evaluate biological activities of the produced astaxanthin. To maximize the astaxanthin yield, the response surface methodology was used so as to optimize the culture conditions. A maximum astaxanthin yield of 1262.08 &plusmn; 14.58 &micro;g/L was achieved by growing R. toruloides G17 in a molasses-based medium containing 49.39 g/L reducing sugar, 1.00 g/L urea, 4.15 g/L MgSO4&middot;7H2O, and 10.05% inoculum ratio. The produced astaxanthin was then purified and studied for its antioxidant and anticancer activities. This compound exhibited 123-fold higher antioxidant activity than &alpha;-tocopherol, with an IC50 value of 0.97 &plusmn; 0.01 &micro;g/mL. The astaxanthin also showed a potent inhibitory ability against the following three cancer cell lines: HeLa, A549, and MCF7, with IC50 values of 69.07 &plusmn; 2.4 &micro;g/mL, 55.60 &plusmn; 2.64 &micro;g/mL, and 56.38 &plusmn; 4.1 &micro;g/mL, respectively. This study indicates that astaxanthin derived from our newly mutated R. toruloides G17 is a promising anticancer and antioxidant agent for further pharmaceutical applications

Investigating the Anti-Inflammatory Activity of Curcumin-Loaded Silica-Containing Redox Nanoparticles

Chronic inflammation is considered as one of the challenging diseases, and overproduction of reactive oxygen species (ROS) is strongly related to the onset of chronic inflammation. Therefore, antioxidant and anti-inflammatory approaches are particularly becoming suitable treatment and prevention of inflammation. Curcumin (CUR), a main component of turmeric extract, is well known as an effective agent in both antioxidant and anti-inflammatory activities; however, there are still some limitations of its use including poor water solubility, low bioavailability, and oxidation by ROS. Nanotechnology has been used as a drug delivery system, which is a promising approach in overcoming the aforementioned drawbacks of CUR; hence, it improves the antioxidant and anti-inflammatory effects of conventional medications. In this research, silica-containing redox nanoparticles (siRNP) were designed with the size of several tens of nanometers, prepared by self-assembly of an amphiphilic block copolymer consisting of drug absorptive silica moiety and ROS-scavenging nitroxide radical moiety in the hydrophobic segment. CUR was simply encapsulated into siRNP through the dialysis method, creating CUR-loaded siRNP (CUR@siRNP), which significantly improved the water solubility of CUR. The efficient antioxidant activity and anti-inflammatory effect of CUR@siRNP in vitro were also improved via 2,2-diphenyl-1-picrylhydrazyl assay and lipopolysaccharide-induced macrophage cell line activation, respectively. Oral administration of CUR@siRNP showed improvement in pharmacokinetic profile in vivo including AUC and Cmax values as compared to free CUR. Furthermore, the anti-inflammatory effect of nanoformulation was investigated in the colitis mouse model induced by dextran sodium sulfate